Baotong Li1, Hengchao Wu1, Hansong Sun2, Jianping Xu1, Yunhu Song1, Wei Wang1, Shuiyun Wang1. 1. State Key Laboratory of Cardiovascular Disease, Department of Adult Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China. 2. State Key Laboratory of Cardiovascular Disease, Department of Adult Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China. drsunhs@sina.com.
Abstract
BACKGROUND: Although it has been realized that restrictive mitral valve annuloplasty (MVA) may re-sult in clinically significant functional mitral stenosis (MS), it still cannot be predicted. The purpose of this study was to identify risk factors for clinically significant functional MS following restrictive MVA surgery for chronic ischemic mitral regurgitation (CIMR). METHODS: One hundred and fourteen patients who underwent restrictive MVA with coronary artery bypass grafting (CABG) for treatment of CIMR were retrospectively reviewed. Clinically significant functional MS was defined as resting transmitral peak pressure gradient (PPG) ≥ 13 mmHg. RESULTS: During the follow-up period (range 6-12 months), 28 (24.56%) patients developed clinically significant functional MS. The PPG at follow-up was significantly higher than that measured in the early postoperative stage (3-5 days after surgery). Moreover, there was a linear correlation between the two measurements (r = 0.398, p < 0.001). Annuloplasty size ≤ 27 mm and early postoperative PPG ≥ 7.4 mmHg could predict clinically significant functional MS at 6-12 months postoperatively. CONCLUSIONS: Chronic ischemic mitral regurgitation patients treated with restrictive MVA and CABG have significant increases in PPG postoperatively. Annuloplasty size ≤ 27 mm and early postopera-tive PPG ≥ 7.4 mmHg can predict clinically significant functional MS at 6-12 months after surgery.
BACKGROUND: Although it has been realized that restrictive mitral valve annuloplasty (MVA) may re-sult in clinically significant functional mitral stenosis (MS), it still cannot be predicted. The purpose of this study was to identify risk factors for clinically significant functional MS following restrictive MVA surgery for chronic ischemic mitral regurgitation (CIMR). METHODS: One hundred and fourteen patients who underwent restrictive MVA with coronary artery bypass grafting (CABG) for treatment of CIMR were retrospectively reviewed. Clinically significant functional MS was defined as resting transmitral peak pressure gradient (PPG) ≥ 13 mmHg. RESULTS: During the follow-up period (range 6-12 months), 28 (24.56%) patients developed clinically significant functional MS. The PPG at follow-up was significantly higher than that measured in the early postoperative stage (3-5 days after surgery). Moreover, there was a linear correlation between the two measurements (r = 0.398, p < 0.001). Annuloplasty size ≤ 27 mm and early postoperative PPG ≥ 7.4 mmHg could predict clinically significant functional MS at 6-12 months postoperatively. CONCLUSIONS:Chronic ischemic mitral regurgitationpatients treated with restrictive MVA and CABG have significant increases in PPG postoperatively. Annuloplasty size ≤ 27 mm and early postopera-tive PPG ≥ 7.4 mmHg can predict clinically significant functional MS at 6-12 months after surgery.
Authors: Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart Journal: J Am Soc Echocardiogr Date: 2005-12 Impact factor: 5.251
Authors: Philippe B Bertrand; Frederik H Verbrugge; David Verhaert; Christophe J P Smeets; Lars Grieten; Wilfried Mullens; Herbert Gutermann; Robert A Dion; Robert A Levine; Pieter M Vandervoort Journal: J Am Coll Cardiol Date: 2015-02-10 Impact factor: 24.094
Authors: Irving L Kron; Michael A Acker; David H Adams; Gorav Ailawadi; Steven F Bolling; Judy W Hung; D Scott Lim; Damien J LaPar; Michael J Mack; Patrick T O'Gara; Michael K Parides; John D Puskas Journal: J Thorac Cardiovasc Surg Date: 2016-02-04 Impact factor: 5.209
Authors: Matthew L Williams; Mani A Daneshmand; James G Jollis; John R Horton; Linda K Shaw; Madhav Swaminathan; Robert D Davis; Donald D Glower; Peter K Smith; Carmelo A Milano Journal: Ann Thorac Surg Date: 2009-10 Impact factor: 4.330
Authors: Julien Magne; Mario Sénéchal; Patrick Mathieu; Jean G Dumesnil; François Dagenais; Philippe Pibarot Journal: J Am Coll Cardiol Date: 2008-04-29 Impact factor: 24.094
Authors: Roberto Lorusso; Sandro Gelsomino; Enrico Vizzardi; Antonio D'Aloia; Giuseppe De Cicco; Fabiana Lucà; Orlando Parise; Gian Franco Gensini; Pierluigi Stefàno; Ugolino Livi; Igor Vendramin; Davide Pacini; Roberto Di Bartolomeo; Antonio Miceli; Egidio Varone; Mattia Glauber; Alessandro Parolari; Francesco Giuseppe Arlati; Francesco Alamanni; Filiberto Serraino; Attilio Renzulli; Antonio Messina; Giovanni Troise; Giovanni Mariscalco; Marzia Cottini; Cesare Beghi; Francesco Nicolini; Tiziano Gherli; Valentino Borghetti; Alessandro Pardini; Philippe-Primo Caimmi; Ezio Micalizzi; Carlo Fino; Paolo Ferrazzi; Michele Di Mauro; Antonio Maria Calafiore Journal: J Thorac Cardiovasc Surg Date: 2012-11-03 Impact factor: 5.209